Acute Coronary Syndrome Market Pipeline H2 2015 and Forecasts of 13% CAGR Growth to 2019 Reviewed in New ACS Research Reports

Aug 19, 2015, 02:00 ET from ReportsnReports

CHICAGO, August 19, 2015 /PRNewswire/ --

Acute Coronary Syndrome - Pipeline Review, H2 2015 and Global Acute Coronary Syndrome (ACS) Market 2015-2019 are the latest research reports that provide an overview of the ACS therapeutic pipeline and market segments like STEMI, NSTEMI, and UA.

Complete report on acute coronary syndrome market pipeline for H2 2015 spread across 115 pages, talking about 16 companies and supported with 33 tables and 13 figures is now available at

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies, identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome as well as plan mergers and acquisitions effectively by identifying key players of the most promising pipeline through this report. It also offers data and information that support in devising corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics. Developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope and modifying the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline becomes easy with the help of this ACS pipeline report.

Companies involved in Acute Coronary Syndrome therapeutics development and mentioned in this research include advanceCor GmbH, Arena Pharmaceuticals, Inc., Artery Therapeutics, Inc., Athera Biotechnologies AB, Bayer AG, Cardiome Pharma Corp., Cerenis Therapeutics Holding SA, Esperion Therapeutics, Inc., GlaxoSmithKline Plc, Lee's Pharmaceutical Holdings Limited, MedImmune, LLC, Pfizer Inc., Teva Pharmaceutical Industries Limited, The Medicines Company, Vitae Pharmaceuticals, Inc. and XOMA Corporation. Drug profiles covered in this report are 4-WF, AEM-28, AEM-28-02, Artpep-2, CER-001, COR-2, COR-3, gevokizumab, losmapimod, MDCO-216, MEDI-6012, PC-mAb, PF-06282999, PMC-6, PR-15, rivaroxaban, SD-970, temanogrel hydrochloride, tirofiban hydrochloride, VTP-38443 and ZK-001. Order a copy of Acute Coronary Syndrome - Pipeline Review, H2 2015 market research report at

The second research titled Global Acute Coronary Syndrome (ACS) Market 2015-2019 segments this industry into STEMI, NSTEMI, and UA with the forecast that worldwide acute coronary syndrome market will grow at 13.24% CAGR during 2014 to 2019. Growing public awareness of ACS is one of the key trends being witnessed in this market. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks. According to the report, the elderly population, from middle-aged and older, are more prone to developing ACS because with aging, plaque accumulates in the arteries, resulting in the narrowing of the arterial passage and difficulty in blood flow to the heart.

Further, the report states that patent expiry of a drug results in the loss of the exclusive market for that particular drug, thus leading to a rapid decline in its sales. Patent expiry of a drug results in the loss of the exclusive market, resulting in a rapid decline in the sales of that particular drug. AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA are the major companies analyzed in this research. Other prominent players of the market simply mentioned in the report are AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals and Teva Pharmaceutical. Supported with 44 data exhibits and spread across 97 pages, the Global Acute Coronary Syndrome (ACS) Market 2015-2019 report is available at

For the pharmaceuticals market stakeholders, has multiple newly published and relevant research titles that might be of interest:

Coronary Guidewires - Pipeline Review, 2015: The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Coronary Guidewires pipeline products. Companies like Boston Scientific Corporation, Computer Vision Systems Laboratories Corp., MaRVis Technologies GmbH, Guided Interventions LLC, MicroPort Scientific Corporation, Occlutech International AB, Opsens Inc. and The Cleveland Clinic Foundation are mentioned in this research supported with 38 tables, 5 figures and spread across 68 pages available at

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023: This research expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). France represents one of the smallest in terms of overall ACS drug sales. Next to the US market, Germany commands the largest global market share for the sale of ACS drugs. Italy's contribution to global sales in both 2013 and 2023 falls in the middle of the sales distribution for the 7MM covered in this forecast. Of the 7MMs that were forecast in this report, Spain's share of global sales is the smallest for both the 2013 base year and the final forecast year of 2023. Of the markets forecast here, the UK commands the third largest market share in both the 2013 base year and in 2023. Read more at

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:


RSS/Feeds:  http: //


Ritesh Tiwari
1 South Dearborn Street
21st Floor, Chicago
Illinois 60603, USA


SOURCE ReportsnReports